Impact of first-line chemoimmunotherapy with or without radiotherapy on the prognosis of patients with locally advanced or metastatic esophageal squamous cell carcinoma: a multicenter, real-world, retrospective cohort study from China (NCT06478355)

作者：Xinyi Liu, Jingyuan Wen, Yaowen Zhang, Chenyu Wang, Yatian Liu, Pudong Qian, Jianzhong Cao, Qing Hou, Yuanji Xu, Zhongmei Lin, Xianghua Ye, Min Hou, Yan Gui, Lulu Wang, Wei Zhou, Zhimin Zeng, Yaqi Song, Honglei Luo, Jiahua Lv, Wenbin Shen · 发表于：Frontiers in Immunology · 年份：2025 · DOI：10.3389/fimmu.2025.1633930 · 被引用次数：3 · 研究领域：Esophageal Cancer Research and Treatment、Cancer Immunotherapy and Biomarkers、Colorectal and Anal Carcinomas

Background: Chemotherapy combined with immunotherapy has already become the standard first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC), whereas there are no satisfying overall survival (OS) and progression-free survival (PFS). This research aims to evaluate whether first-line chemoimmunotherapy combined with radiotherapy (RT) improves outcomes and safety in patients who suffer from locally advanced and metastatic ESCC. Methods: A total of 664 patients who suffer from locally advanced or metastatic ESCC going through first-line chemoimmunotherapy with or without radiotherapy at China's 11 large cancer centers from Jan. 2019 to Dec. 2022 were retrospectively explored. Each patient received first-line chemoimmunotherapy, and the specific program was determined by the investigator. Regarding the radiotherapy group, each patient went through radiotherapy with a dose of ≥30 Gy to the primary lesion. Through utilizing the log-rank test, Kaplan-Meier survival curves were set up and then compared. The research carried out prognostic analysis by harnessing the univariate and multivariate Cox proportional hazards regression models. To find out patient characteristics and treatment patterns related to treatment responses, we also conducted subgroup analyses. The possible biases were minimized through performing the propensity score matching (PSM). This trial has been registered at ClinicalTrials.gov (NCT06478355, Registration date: June 22, 2024). ...